Location Buffalo, New York, United States Regions Great Lakes, East Coast, Northeastern US Gender Male
Facebook View on Facebook LinkedIn View on LinkedIn
Dr. Hangauer is a leader in the field of structure based drug design. Following doctoral studies in chemistry at the University at Buffalo, he spent ten years at Merck Sharp and Dohme Research Laboratories where he directed a variety of drug discovery projects. In 1989, he returned to academia and joined the chemistry faculty at SUNY at Buffalo
where he has had a productive career that has focused on developing protein kinase inhibitors.
Dr. Hangauer’s expertise has been sought by pharmaceutical and biotechnology companies worldwide, including Lederle /Wyeth-Ayerst Research Laboratories, New Medical Technologies, Sphinx/Eli Lilly Pharmaceuticals Inc., Yuhan Corporation, Periodontix, Inc., ICAgen, Inc., ARPIDA, Scientific Advisory Board & Founding Scientist and Signal Pharmaceuticals, Inc..
Most notably he led the chemistry effort at Hypnion, Inc., that resulted in the discovery and development of an insomnia drug. The Company was sold to Eli Lilly in 2009 for more than $300 million and its major asset was the insomnia drug that was designed and discovered under the leadership of Dr. Hangauer.
